Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
122.92
-3.48 (-2.75%)
At close: Mar 28, 2025, 4:00 PM
125.00
+2.08 (1.69%)
After-hours: Mar 28, 2025, 5:42 PM EDT
Jazz Pharmaceuticals Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Jazz Pharmaceuticals stock have an average target of 187.15, with a low estimate of 150 and a high estimate of 230. The average target predicts an increase of 52.25% from the current stock price of 122.92.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Jazz Pharmaceuticals stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 6 | 6 | 6 | 6 | 6 | 7 |
| Hold | 3 | 3 | 3 | 3 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 14 | 14 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $200 → $217 | Strong Buy | Maintains | $200 → $217 | +76.54% | Mar 10, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $175 → $183 | Buy | Initiates | $175 → $183 | +48.88% | Mar 7, 2025 |
| UBS | UBS | Hold → Strong Buy Upgrades $145 → $179 | Hold → Strong Buy | Upgrades | $145 → $179 | +45.62% | Mar 7, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $220 → $230 | Strong Buy | Maintains | $220 → $230 | +87.11% | Mar 6, 2025 |
| Needham | Needham | Strong Buy Reiterates $210 | Strong Buy | Reiterates | $210 | +70.84% | Mar 5, 2025 |
Financial Forecast
Revenue This Year
4.37B
from 4.07B
Increased by 7.30%
Revenue Next Year
4.54B
from 4.37B
Increased by 4.01%
EPS This Year
22.38
from 8.65
Increased by 158.74%
EPS Next Year
22.95
from 22.38
Increased by 2.57%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.6B | 5.1B | 5.5B | ||
| Avg | 4.4B | 4.5B | 4.8B | ||
| Low | 4.1B | 4.0B | 4.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.5% | 16.4% | 20.4% | ||
| Avg | 7.3% | 4.0% | 6.4% | ||
| Low | 0.6% | -7.9% | -11.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.73 | 26.41 | 29.09 | ||
| Avg | 22.38 | 22.95 | 25.82 | ||
| Low | 18.17 | 17.13 | 15.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 209.1% | 18.0% | 26.7% | ||
| Avg | 158.7% | 2.6% | 12.5% | ||
| Low | 110.1% | -23.4% | -33.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.